title: [From results of BEAUTIFUL trial to results of SHIFT trial: BEAUTIFUL possibility to make a SHIFT in current guidelines].
abstract: The article is devoted to results of randomized clinical trails BEAUTIFUL and SHIFT. Position of If-inhibitor ivabradine in current guidelines on management of patients with stable angina and heart failure is discussed.
authors.forename: Iu M
authors.initials: IuM
authors.lastname: Lopatin
mesh_terms: D000787:Angina Pectoris / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D001552:Benzazepines / Q000627:therapeutic use*; D002317:Cardiovascular Agents / Q000627:therapeutic use; D054815:Cyclic Nucleotide-Gated Cation Channels / Q000378:metabolism; D018450:Disease Progression; D019317:Evidence-Based Medicine; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects; D006760:Hospitalization; D006801:Humans; D000077550:Ivabradine; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic
chemical_list: D001552:Benzazepines; D002317:Cardiovascular Agents; D054815:Cyclic Nucleotide-Gated Cation Channels; D000077550:Ivabradine